生化复发前列腺癌患者中18F-PSMA-1007非特异性骨摄取的PSMA-11 PET、骨扫描与MRI三重验证评估
该研究对生化复发前列腺癌患者分别行18F-PSMA-1007与68Ga-PSMA-11 PET,比较非特异性骨摄取(UBU)与骨转移率,并对18F-PSMA-1007 UBU患者追加68Ga-PSMA-11 PET、骨扫描和MRI验证。18F-PSMA-1007组UBU率显著高于68Ga-PSMA-11组(140 vs 64,P<0.001),骨转移率无显著差异(72 vs 64,P=0.7);在PSA≤5 ng/mL且SUV>4者中,18F-PSMA-1007局灶骨摄取多为假阳性。
要点
- 18F-PSMA-1007组UBU率显著高于68Ga-PSMA-11组(140 vs 64,P<0.001)。
- 两组骨转移率无显著差异(72 vs 64,P=0.7)。
- PSA≤5 ng/mL且SUV>4时,18F-PSMA-1007局灶骨摄取患者水平阳性预测值8.3%、病灶水平3.6%。
核心结论
- 在生化复发且PSA≤5 ng/mL、SUV>4的患者中,多数18F-PSMA-1007局灶骨摄取很可能是假阳性,归因于UBU。
- 临床转移可能性低时,无形态学对应的18F-PSMA-1007骨摄取应结合定位与临床背景谨慎评估。
- 临床常规中18F-PSMA-1007骨转移率并未更高,提示有经验的报告医师会针对UBU进行调整。
研究设计与样本
- 回顾性纳入2020年1月至2020年12月行68Ga-PSMA-11 PET的生化复发患者383例,以及2020年1月至2021年11月行18F-PSMA-1007 PET的生化复发患者409例,进行个体间比较。
- 个体内比较纳入18F-PSMA-1007 UBU患者(定义为局灶骨摄取SUVmax>4且PSA≤5 ng/mL)中追加68Ga-PSMA-11 PET者17例,其中12例在1至5周间隔内另行骨扫描与全身MRI。
主要发现
- 18F-PSMA-1007组UBU率显著高于68Ga-PSMA-11组(140 vs 64,P<0.001)。
- 两组骨转移率无显著差异(72 vs 64,P=0.7)。
- 个体内比较组中,经CT、MRI、骨扫描和68Ga-PSMA-11 PET验证,18F-PSMA-1007局灶骨摄取(平均SUVmax 6.1±2.9)患者水平阳性预测值为8.3%,病灶水平为3.6%。
关键数值与推荐
- UBU定义:18F-PSMA-1007局灶骨摄取SUVmax>4且PSA≤5 ng/mL。
- 假阳性定义:18F-PSMA-1007可见骨摄取而CT、MRI(n=1)、骨扫描和68Ga-PSMA-11 PET均未见。
临床怎么用
- 在PSA≤5 ng/mL且SUV>4的生化复发患者中,多数18F-PSMA-1007局灶骨摄取很可能是假阳性,归因于UBU。
- 临床转移可能性低时,无形态学对应的18F-PSMA-1007骨摄取应结合定位与临床背景谨慎评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-PSMA-1007 PET is used in the management of patients with prostate cancer. However, recent reports indicate a high rate of unspecific bone uptake (UBU) with 18F-PSMA-1007, which may lead to a false-positive diagnosis. UBU has not been evaluated thoroughly. Here, we evaluate the frequency of UBU and bone metastases separately for 18F-PSMA-1007 and 68Ga-PSMA-11 in biochemical recurrence (interindividual comparison). Additionally, we investigate UBU seen in 18F-PSMA-1007 through follow-up examinations (intraindividual comparison) using 68Ga-PSMA-11 PET, bone scintigraphy, and MRI. Methods: First, all patients (n = 383) who underwent 68Ga-PSMA-11 PET between January 2020 and December 2020 and all patients (n = 409) who underwent 18F-PSMA-1007 PET between January 2020 and November 2021 due to biochemical recurrence were included for an interindividual comparison of bone metastases and UBU rate. In a second approach, we regarded all patients with UBU in 18F-PSMA-1007, characterized by focal bone uptake with an SUVmax > 4 and prostate-specific antigen (PSA) ≤ 5 ng/mL, who underwent additional 68Ga-PSMA-11 PET (n = 17) (interindividual comparison). Of these, 12 patients also had bone scintigraphy and whole-body MRI within a 1- to 5-wk interval. Bone uptake seen on 18F-PSMA-1007 but not on any of the other 4 modalities (CT, MRI [n = 1], bone scanning, and 68Ga-PSMA-11 PET) was recorded as false-positive. Results: Patients scanned with 18F-PSMA-1007 PET had a significantly higher rate of UBU than those scanned with 68Ga-PSMA-11 (140 vs. 64; P < 0.001); however, the rate of bone metastases was not significantly different (72 vs. 64; P = 0.7). In the intraindividual comparison group, workup by CT, MRI, bone scanning, and 68Ga-PSMA-11 PET resulted in a positive predictive value for 18F-PSMA-1007 focal bone uptake (mean SUVmax, 6.1 ± 2.9) per patient and per lesion of 8.3% and 3.6%, respectively. Conclusion: In patients with PSA ≤ 5 ng/mL and SUV > 4 at biochemical recurrence, most 18F-PSMA-1007 focal bone uptake is likely to be false-positive and therefore due to UBU. In the case of low clinical likelihood of metastatic disease, 18F-PSMA-1007 bone uptake without morphologic surrogate should be assessed carefully with regard to localization and clinical context. However, the rate of bone metastases was not higher with 18F-PSMA-1007 in the clinical routine, indicating that experienced reporting physicians adjust for UBU findings.
引用
- Seifert R, Telli T, Opitz M, et al. Unspecific 18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med. 2022. PMID: 36460340. doi:10.2967/jnumed.118.215434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。